AU2006218054A1 - Novel pyrrolodihydroisoquinolines as PDE10 inhibitors - Google Patents

Novel pyrrolodihydroisoquinolines as PDE10 inhibitors Download PDF

Info

Publication number
AU2006218054A1
AU2006218054A1 AU2006218054A AU2006218054A AU2006218054A1 AU 2006218054 A1 AU2006218054 A1 AU 2006218054A1 AU 2006218054 A AU2006218054 A AU 2006218054A AU 2006218054 A AU2006218054 A AU 2006218054A AU 2006218054 A1 AU2006218054 A1 AU 2006218054A1
Authority
AU
Australia
Prior art keywords
alkyl
hydrogen
alkoxy
methyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006218054A
Other languages
English (en)
Inventor
Thomas Baer
Juergen Braunger
Paola Ciapetti
Jean-Marie Contreras
Matthias Vennemann
Camille Georges Wermuth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Nycomed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed GmbH filed Critical Nycomed GmbH
Publication of AU2006218054A1 publication Critical patent/AU2006218054A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2006218054A 2005-01-12 2006-01-11 Novel pyrrolodihydroisoquinolines as PDE10 inhibitors Abandoned AU2006218054A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05100154 2005-01-12
EP05100154.3 2005-01-12
PCT/EP2006/050167 WO2006089815A1 (en) 2005-01-12 2006-01-11 Novel pyrrolodihydroisoquinolines as pde10 inhibitors

Publications (1)

Publication Number Publication Date
AU2006218054A1 true AU2006218054A1 (en) 2006-08-31

Family

ID=36097003

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006218054A Abandoned AU2006218054A1 (en) 2005-01-12 2006-01-11 Novel pyrrolodihydroisoquinolines as PDE10 inhibitors

Country Status (9)

Country Link
US (1) US20080161338A1 (https=)
EP (1) EP1838707B1 (https=)
JP (1) JP2008526818A (https=)
AT (1) ATE430148T1 (https=)
AU (1) AU2006218054A1 (https=)
CA (1) CA2593750A1 (https=)
DE (1) DE602006006544D1 (https=)
ES (1) ES2326337T3 (https=)
WO (1) WO2006089815A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20050945A (sr) * 2003-06-30 2008-06-05 Altana Pharma Ag., Novi pirolodihidroizohinolini koji se mogu upotrebiti u tretmanu kancera
CA2595075A1 (en) * 2005-01-12 2006-07-20 Matthias Vennemann Pyrrolodihydroisoquinolines as antiproliferative agents
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
KR20100110804A (ko) * 2007-11-30 2010-10-13 와이어쓰 엘엘씨 포스포디에스테라제 10의 저해물질로서의 아릴 및 헤테로아릴 융합된 이미다조[1,5-ａ]피라진
TW200944523A (en) 2008-02-08 2009-11-01 Organon Nv (Dihydro)pyrrolo[2,1-a]isoquinolines
CA2827724A1 (en) 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
GB201117453D0 (en) * 2011-10-10 2011-11-23 Univ Dundee Improved sperm function/activity
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
CN119367368B (zh) * 2024-11-28 2025-12-05 中山大学 氮杂四元环连接的吡唑并吡啶类化合物在制备治疗肺动脉高压的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761358B1 (fr) * 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6930114B2 (en) * 2000-12-13 2005-08-16 Bayer Pharmaceuticals Corporation Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors
US20030018047A1 (en) * 2001-04-20 2003-01-23 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) * 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
WO2003014115A1 (en) * 2001-08-06 2003-02-20 Bayer Aktiengesellschaft 3-substituted pyrrolo (2.1-a) isoquinoline derivatives
WO2003051877A1 (en) * 2001-12-18 2003-06-26 Bayer Corporation 2-substituted pyrrolo[2.1-a]isoquinolines against cancer
RS20050945A (sr) * 2003-06-30 2008-06-05 Altana Pharma Ag., Novi pirolodihidroizohinolini koji se mogu upotrebiti u tretmanu kancera

Also Published As

Publication number Publication date
WO2006089815A1 (en) 2006-08-31
EP1838707A1 (en) 2007-10-03
EP1838707B1 (en) 2009-04-29
US20080161338A1 (en) 2008-07-03
DE602006006544D1 (de) 2009-06-10
ATE430148T1 (de) 2009-05-15
CA2593750A1 (en) 2006-08-31
JP2008526818A (ja) 2008-07-24
ES2326337T3 (es) 2009-10-07

Similar Documents

Publication Publication Date Title
AU2004253690B2 (en) Pyrrolodihydroisoquinolines as PDE10 inhibitors
EP1641457B1 (en) Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
KR101478517B1 (ko) Ｎ1-피라졸로스피로케톤 아세틸-ｃｏａ 카복실라아제 억제제
SG174632A1 (en) Quinolinone derivatives
CN108026080B (zh) 吡唑基取代的杂芳基化合物及其作为药物的用途
FR2974088A1 (fr) Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux
CA2330738A1 (en) Novel n-oxides of benzonaphthyridines
AU5317098A (en) Benzonaphthyridines as bronchial therapeutics
EP1838707B1 (en) Novel pyrrolodihydroisoquinolines as pde10 inhibitors
JP2018515489A (ja) ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法
TW202530189A (zh) ３－苯基丙基胺衍生物
MXPA06009892A (es) Nuevas hidroxi-6-fenilfenantridinas sustituidas con amido y su uso como inhibidores de la fosfodiesterasa tipo 4 (pde4).
WO2014072930A2 (en) Fused pyridine derivatives as antibacterial agents
TW202342013A (zh) 雜環化合物、其組成物及用其進行治療之方法
EP1732925A1 (en) Novel n-(alkoxyalkyl)carbamoyl- substituted 6-phenyl-benzonaphthyridine derivatives and their use as pde3/4 inhibitors
US20080064714A1 (en) Novel Pyrrolodihydroisoquinolines
AU2003264132B2 (en) Novel benzonaphthyridines
HK1185079A1 (zh) 新型二环式化合物或其盐

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND CO-INVENTORS TO READ WERMUTH, CAMILLE GEORGES; CONTRERAS, JEAN-MARIE; CIAPETTI, PAOLA; VENNEMANN, MATTHIAS; BAER, THOMAS AND BRAUNGER, JUERGEN

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application